scholarly journals Kaposi's sarcoma a series of cases and review of the literature

2021 ◽  
Vol 11 (4) ◽  
pp. 104-108
Author(s):  
Maria Valeria Jiménez Báez
Keyword(s):  
High Risk ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Quintana Roo ◽  
Therapeutic Trials ◽  
Immunodeficiency Virus ◽  
Oncological Diseases ◽  
Advanced Stages ◽  
Hiv Aids

Introduction: Kaposi's sarcoma is a neoplasm associated with the Human Immunodeficiency Virus (HIV) - AIDS especially in advanced stages, in Quintana Roo HIV-AIDS ranks first in the country. Methodology: A series of 22 cases with diagnosis confirmed by biopsy attended by the oncology service of HGR No. 17 is presented. Results: They were classified as low risk (4); three of them with complete response. High risk (18); fifteen accepted chemotherapy. Nine (60%) received liposomal doxorubicin and six (40%) paclitaxel; of these, four had a complete response, one partial response, six with stable disease and five with disease progression that required a second line. The presence of adverse effects associated with chemotherapy treatment was documented in six patients classified as high risk (40%). Conclusions: Clinical interventions with therapeutic trials are necessary, since the available evidence dates from periods of more than 10 years ago. HIV patients require continuous monitoring and clinical trials to improve the therapeutic options available to treat one of the most common oncological diseases in this population such as Kaposi's Sarcoma.

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

1998 ◽  
Vol 16 (3) ◽  
pp. 1112-1121 ◽  
Author(s):  
L Welles ◽  
M W Saville ◽  
J Lietzau ◽  
J M Pluda ◽  
K M Wyvill ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Kaposi's Sarcoma ◽  
Single Agent ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Pulmonary Involvement ◽  
Dose Titration ◽  
Treatment Schedule ◽  
Creatinine Concentration ◽  
Immunodeficiency Virus

PURPOSE To investigate the antitumor activity and safety of paclitaxel in patients with advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Twenty-nine patients with advanced HIV-associated KS were enrolled. The patients were overall quite immunosuppressed (median CD4 count, 15 cells/microL). Paclitaxel was initially administered at 135 mg/m2 over 3 hours every 3 weeks without filgrastim support; the dose was increased as tolerated to a maximum of 175 mg/m2. Patients who failed to respond or progressed could then receive filgrastim support or paclitaxel administered over 96 hours. RESULTS Of 28 assessable patients, 20 had major responses (18 partial responses [PRs], one clinical complete response [CR], and one CR), for a major response rate of 71.4% (95% confidence interval [CI], 51.3% to 86.8%). Each of the five patients with pulmonary KS responded, as did all four assessable patients who had previously received anthracycline therapy for KS. Of six patients who went on to receive a 96-hour infusion of paclitaxel, five had major responses. Neutropenia was the most frequent dose-limiting toxicity; possible novel toxicities included late fevers, late rash, and eosinophilia. Two patients developed an elevated creatinine concentration and one cardiomyopathy. CONCLUSION Paclitaxel has substantial activity against advanced HIV-associated KS as a single agent, even in patients with pulmonary involvement or who had previously received anthracyclines. Further research is needed to define the optimal treatment schedule and its role vis-a-vis the other available therapies for this disease.

scholarly journals Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma

2002 ◽  
Vol 76 (22) ◽  
pp. 11570-11583 ◽  
Author(s):  
Brian R. Lane ◽  
Jianguo Liu ◽  
Paul J. Bock ◽  
Dominique Schols ◽  
Michael J. Coffey ◽  
...  
Keyword(s):  
Cell Culture ◽  
Endothelial Cells ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Interleukin 8 ◽  
Cellular Growth ◽  
Immunodeficiency Virus ◽  
Hiv 1 ◽  
Stimulation Of

ABSTRACT The development of the complex neoplasm Kaposi's sarcoma is dependent on infection with the Kaposi's sarcoma-associated herpesvirus (KSHV) and appears to be greatly enhanced by cytokines and human immunodeficiency virus type 1 (HIV-1) Tat. Interleukin-8 (IL-8) and growth-regulated oncogene alpha (GRO-α) are chemokines involved in chemoattraction, neovascularization, and stimulation of HIV-1 replication. We have previously demonstrated that production of GRO-α is stimulated by exposure of monocyte-derived macrophages (MDM) to HIV-1. Here we show that exposure of MDM to HIV-1, viral Tat, or viral gp120 leads to a substantial increase in IL-8 production. We also demonstrate that IL-8 and GRO-α are induced by KSHV infection of endothelial cells and are crucial to the angiogenic phenotype developed by KSHV-infected endothelial cells in cell culture and upon implantation into SCID mice. Thus, the three known etiological factors in Kaposi's sarcoma pathogenesis—KSHV, HIV-1 Tat, and cellular growth factors—might be linked, in part, through induction of IL-8 and GRO-α.

scholarly journals Primary Gastrointestinal Kaposi’s Sarcoma in a Patient with Human Immunodeficiency Virus

2018 ◽  
Vol 11 (3) ◽  
pp. 638-647 ◽  
Author(s):  
Martin Ignacio Zapata Laguado ◽  
Jorge Enrique Aponte Monsalve ◽  
Jorge Hernan Santos ◽  
Javier Preciado ◽  
Andres Mosquera Zamudio ◽  
...  
Keyword(s):  
Gastrointestinal Bleeding ◽  
Kaposi's Sarcoma ◽  
Gastrointestinal Endoscopy ◽  
Rare Complication ◽  
Kaposi’S Sarcoma ◽  
Skin Lesions ◽  
Clinical Findings ◽  
Upper Gastrointestinal Endoscopy ◽  
Immunodeficiency Virus ◽  
Upper Gastrointestinal

Gastrointestinal bleeding in HIV patients secondary to coinfection by HHV8 and development of Kaposi’s sarcoma (KS) is a rare complication even if no skin lesions are detected on physical examination. This article indicates which patients might develop this type of clinical sign and also tries to recall that absence of skin lesions never rules out the presence of KS, especially if gastrointestinal involvement is documented. Gastrointestinal bleeding in terms of hematemesis has rarely been reported in the literature. We review some important clinical findings, diagnosis, and treatment approach. We present the case of an HIV patient who presented to the emergency department with hematemesis and gastrointestinal signs of KS on upper gastrointestinal endoscopy without any dermatological involvement.

scholarly journals Therapeutic Outcomes in AIDS-Associated Kaposi's Sarcoma Patients on Antiretroviral Therapy Treated with Chemotherapy at Two Tertiary Hospitals in Lusaka, Zambia

2018 ◽  
Vol 16 (3) ◽  
pp. 231-236 ◽  
Author(s):  
Watson Mtonga ◽  
Aaron Mujajati ◽  
Derick Munkombwe ◽  
Aubrey Kalungia ◽  
Lungwani Tyson Muungo ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
University Teaching ◽  
Teaching Hospitals ◽  
Recurrence Rates ◽  
Therapeutic Outcomes ◽  
Efficacious Treatment ◽  
Study Participants

The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

Sign in / Sign up

Export Citation Format

Share Document